IP Verse

Ammelburg competitive analysis

Loading summary...

Explore patent oppositions filed by Ammelburg against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 23, 2025

Patent Number	Title	Applicant	Opposition Date
Get instant updates on new opposition filings by the company
EP4219687	Methods For Isolating, Culturing, And Genetically Engineering Immune Cell Populations For Adoptive Therapy	JUNO THERAPEUTICS	May 14, 2025
EP3400947	Modulation Of Apolipoprotein C-Iii (Apociii) Expression In Lipoprotein Lipase Deficient (Lpld) Populations	IONIS PHARMACEUTICALS	May 22, 2024
EP3607069	Products And Compositions	SILENCE THERAPEUTICS	Jul 31, 2023
EP3895712	Engineered Natural Killer Cells And Uses Thereof	ONK THERAPEUTICS	Mar 21, 2023
EP3213085	Biomarkers For Risk Prediction Of Mortality	F HOFFMANN LA ROCHE	Sep 12, 2019
EP3016654	Tauroursodeoxycholic Acid (Tudca) For Use In The Treatment Of Neurodegenerative Disorders	BRUSCHETTINI	Jun 4, 2019

Explore the latest publications and patents granted to Ammelburg, showcasing their recent innovations and technological advancements.

Discover the latest PTAB cases involving Ammelburg, highlighting their recent legal challenges and patent disputes.

IP litigation analysis comparing Ammelburg with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
AMMELBURG	6	-	-	-
BRUSCHETTINI	1	1	-	-
F HOFFMANN LA ROCHE	16	140	-	-
IONIS PHARMACEUTICALS	1	17	-	-